Literature DB >> 8697798

Cardiovascular toxicity with cancer chemotherapy.

W H Frishman1, H M Sung, H C Yee, L L Liu, A I Einzig, J Dutcher, D Keefe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8697798

Source DB:  PubMed          Journal:  Curr Probl Cardiol        ISSN： 0146-2806            Impact factor:   5.200


× No keyword cloud information.
  6 in total

1.  Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel.

Authors:  Guenther G Steger; Jitka Abrahámová; Florin Bacanu; Stephen Brincat; Arija Brize; Alvydas Cesas; Tanja Cufer; Magdolna Dank; Renata Duchnowska; Alexandru Eniu; Jacek Jassem; Zsuzsanna Kahán; Erika Matos; Peeter Padrik; Signe Plāte; Helis Pokker; Gunta Purkalne; Constanta Timcheva; Valentina Tzekova; Rostislav Vyzula; Christoph C Zielinski
Journal:  Wien Klin Wochenschr       Date:  2010-06-15       Impact factor: 1.704

2.  Inhibition of the PI3K/AKT Pathway Sensitizes Oral Squamous Cell Carcinoma Cells to Anthracycline-Based Chemotherapy In Vitro.

Authors:  Dmitriy Smolensky; Kusum Rathore; Jennifer Bourn; Maria Cekanova
Journal:  J Cell Biochem       Date:  2017-05-16       Impact factor: 4.429

3.  Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198).

Authors:  Chun Cai; Leonard Lothstein; R Ray Morrison; Polly A Hofmann
Journal:  J Pharmacol Exp Ther       Date:  2010-07-28       Impact factor: 4.030

4.  Cardiomyopathy Caused by Antineoplastic Therapies.

Authors:  Valeriano C. Simbre II; M. Jacob Adams; Sampada S. Deshpande; Sarah A. Duffy; Tracie L. Miller; Steven E. Lipshultz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-12

5.  Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies.

Authors:  Nivesh K Mittal; Bivash Mandal; Pavan Balabathula; Saini Setua; Dileep R Janagam; Leonard Lothstein; Laura A Thoma; George C Wood
Journal:  Pharmaceutics       Date:  2018-04-15       Impact factor: 6.321

6.  Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro.

Authors:  Dmitriy Smolensky; Kusum Rathore; Maria Cekanova
Journal:  BMC Cancer       Date:  2015-11-23       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.